Canine Growth Hormone Disorder (Pituitary Dwarfism) – NAVLE Study Guide

Overview and Clinical Importance

Pituitary dwarfism (also known as juvenile-onset panhypopituitarism or combined pituitary hormone deficiency [CPHD]) is a rare, inherited disorder characterized by deficiency of growth hormone (GH) and other anterior pituitary hormones. This condition results from failure of the pars distalis of the pituitary gland to develop properly during gestation, leading to proportionate dwarfism and multiple endocrine deficiencies.

This endocrinopathy is clinically significant because affected dogs present with distinctive physical features, dermatological abnormalities, and progressive organ dysfunction. Understanding the pathophysiology, diagnosis, and treatment options is essential for the NAVLE, particularly recognizing breed predispositions and the classic clinical presentation.

Etiology and Pathophysiology

Genetic Basis

Pituitary dwarfism in German Shepherd Dogs and related breeds is caused by a simple autosomal recessive mutation in the LHX3 gene located on chromosome 9. LHX3 encodes a LIM homeodomain transcription factor essential for pituitary gland development. The specific mutation involves a 7-base pair deletion in intron 5 of the LHX3 gene, which reduces the intron size to 68 base pairs. This contraction leads to deficient splicing of the LHX3 transcript, resulting in aberrant mRNA and failure of normal pituitary cell differentiation.

Pathophysiology of Hormone Deficiencies

The underdevelopment of the adenohypophysis results in a combined pituitary hormone deficiency affecting multiple hormonal axes:

Secondary Changes

Pituitary Cysts: Intrapituitary cysts frequently develop in the Rathke's pouch area. While previously thought to cause pressure atrophy of the adenohypophysis, current understanding suggests these cysts are a consequence rather than a cause of the underlying genetic defect. CT or MRI imaging often reveals these cystic structures.

Renal Underdevelopment: GH and IGF-1 play critical roles in kidney development. Their deficiency leads to reduced glomerular filtration rate and predisposes affected dogs to progressive chronic kidney disease (CKD).

Breed Predisposition and Epidemiology

German Shepherd Dogs (GSD) are by far the most commonly affected breed. Related breeds carrying the same LHX3 mutation include:

• Saarloos Wolfdog (31% carrier frequency)
• Czechoslovakian Wolfdog (21% carrier frequency)
• White Swiss Shepherd Dog
• Tibetan Terrier
• Karelian Bear Dog
• Lapponian Herder

Sporadic cases have also been reported in Spitz-type dogs, Miniature Pinschers, Weimaraners, Dachshunds, Corgis, and Basset Hounds. There is no sex predilection. An estimated 20% of German Shepherds carry the defective gene.

Clinical Signs and Physical Examination Findings

Age of Onset and Early Recognition

Affected puppies are indistinguishable from normal littermates until approximately 2 months of age. After this point, growth retardation becomes evident compared to siblings. By 3-4 months of age, the characteristic features are typically obvious, particularly retention of the puppy coat and failure to develop primary guard hairs.

Classic Clinical Presentation

Memory Aid - "DWARF GSD": Delayed growth and dentition, Woolly puppy coat retained, Alopecia bilaterally symmetrical, Reproductive abnormalities, Fox-like appearance, GH and TSH deficient, Skin infections common, Dullness develops over time

Diagnostic Approach

Diagnosis is based on clinical presentation combined with laboratory and imaging findings. In breeds with known LHX3 mutations, genetic testing is now the gold standard and often eliminates the need for complex hormonal stimulation tests.

Diagnostic Testing Options

Differential Diagnosis

When evaluating a dog with growth retardation, consider:

• Congenital hypothyroidism: Often causes disproportionate dwarfism (shortened limbs)
• Portosystemic shunt: Poor growth, neurological signs, abnormal liver enzymes
• Malnutrition/Malabsorption: Poor body condition, GI signs
• Skeletal dysplasias (achondroplasia): DISPROPORTIONATE dwarfism with shortened limbs
• Mucopolysaccharidosis: Skeletal abnormalities, facial dysmorphism

Treatment Options

Treatment aims to replace deficient hormones and improve quality of life. Canine growth hormone is not commercially available, necessitating alternative approaches.

Treatment Recommendations

• All affected dogs should receive levothyroxine supplementation, as this is the most important therapy for extending survival
• For optimal growth outcomes, initiate GH or progestin therapy before growth plate closure (before 10-18 months in large breeds)
• Ovariohysterectomy is recommended before progestin therapy in females to prevent pyometra
• Monitor blood glucose during GH and progestin therapy (diabetogenic effects)
• Treat secondary skin infections with appropriate antimicrobials

Prognosis and Complications

Survival Times

• Untreated: 3-5 years average survival; most die or are euthanized by age 5
• Treated with levothyroxine: Significantly extended survival; some dogs live 7-13 years
• Combination therapy (levothyroxine + progestins/GH): May provide additional benefits including protection against CKD

Common Complications

• Progressive chronic kidney disease - common cause of death
• Atlanto-axial malformation - can cause neurological signs and sudden death
• Recurrent skin infections
• Pituitary cyst expansion

Prevention and Breeding Recommendations

Genetic testing before breeding is essential to prevent this disease. With the availability of the LHX3 genetic test, this condition could theoretically be eradicated from affected breeds.

• Affected dogs (homozygous): Should NOT be bred (typically infertile anyway)
• Carrier dogs (heterozygous): Can be bred ONLY to tested-clear dogs to maintain genetic diversity while preventing affected offspring
• Clear dogs: Safe to breed to any tested dog